Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target

Ligand Pharmaceuticals is attractive because its royalty-heavy model generates high-margin, recurring cash flow from commercial drugs while limiting direct development risk, and Q2/26 showed that strength with total revenue of $63.7MM, up 34% year over year, and adjusted core EPS of $2.37. Its outlook is further supported by a deep and expanding portfolio after the XOMA acquisition closed in July 2026, which added 7 commercial-stage products, roughly 14 late-stage programs, and more than doubled the asset base to 200+ programs while cutting XOMA OPEX from about $30MM to under $5MM. In addition, about $1.36B in cash and short-term investments, roughly $700MM of deployable capital, and 7 pivotal readouts expected by the end of 2027 give it substantial optionality for accretive deals, milestone upside, and future royalty growth.

Ligand Pharmaceuticals is viewed negatively because its downside scenario assumes no terminal value after 10-years, implying that the long-term earnings base could erode materially rather than compound. The core risk is that royalty-bearing commercial products may face enough competition to generate minimal cash flows after Yr 10, while newly commercialized products and pipeline drugs could also underperform expectations. In addition, the outlook is weakened by the possibility of a value-destructive deal, which could impair the company’s capital allocation and reduce shareholder value further.